secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628908-25-000132
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q3 Adj EBITDA $39M (8.1% margin); new CFO Ramos; 2026 revenue forecast $2.5B
--------------------------------------------------------------------------------

- Q3 revenue $479.5M, net loss $26.9M; adjusted EBITDA $39.0M vs $31.8M YoY.
- Two new customer agreements bring YTD total to 13; >$750M new annualized revenue to launch in 2026.
- Mario Ramos appointed CFO effective Jan 1, 2026; John Johnson becomes Chief Strategy Officer.
- New CFO Ramos receives $550K base salary, $625K bonus, $100K sign-on bonus, and $2.35M RSU grant.
- Katie DiPerna named COO; Emily Rafferty transitions to EVP Customer Success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000132/0001628908-25-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000132/evh-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628908-25-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer